Background/Aims: Verbal fluency patterns can assist in differential diagnosis during neuropsychological assessment and identify individuals at risk for developing Alzheimer's disease (AD). While evidence suggests that subjects with AD perform worse on category fluency than letter fluency tasks, the pattern in mild cognitive impairment (MCI) is less well known. Methods: Performance on the Controlled Oral Word Association Test (COWAT) and Animal fluency was compared in control, amnestic MCI, non-amnestic MCI, and AD groups. The sample included 136 participants matched for age, education, and gender. Results: Both MCI groups performed similarly with a category > letter fluency pattern rather than a category < letter fluency pattern typically observed in AD. The pattern in MCI, albeit relatively more impaired than in controls, was more similar to healthy controls who exhibited a category > letter fluency pattern. Conclusion: MCI using a category < letter fluency pattern may not represent AD; however, future research requires longitudinal studies of pattern analysis.

Keywords:
Neuropsychological assessment, Cognitive impairment, Semantic fluency, Phonetic fluency, Mild cognitive impairment, Dementia, Alzheimer’s disease
1.
Baldo JV, Schwartz S, Wilkins D, Dronkers NF: Role of frontal versus temporal cortex in verbal fluency as revealed by voxel-based lesion symptom mapping. J Int Neuropsychol Soc 2006;12:896-900.
2.
Gourovitch ML, Kirkby BS, Goldberg TE, Weinberger DR, Gold JM, Esposito G, Van Horn JD, Berman KF: A comparison of rCBF patterns during letter and semantic fluency. Neuropsychology 2000;14:353-360.
3.
Henry JD, Crawford JR, Phillips LH: Verbal fluency performance in dementia of the Alzheimer's type: a meta-analysis. Neuropsychologia 2004;42:1212-1222.
4.
Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E: Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-308.
5.
Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Backman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, de Leon M, DeCarli C, Erkinjuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, van Duijn C, Visser P, Petersen RC: Mild cognitive impairment - beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004;256:240-246.
6.
Petersen RC: Mild cognitive impairment as a diagnostic entity. J Intern Med 2004;256:183-194.
7.
Morris JC, Storandt M, Miller JP, McKeel DW, Price JL, Rubin EH, Berg L: Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 2001;58:397-405.
8.
Economou A, Papageorgiou SG, Karageorgiou C, Vassilopoulos D: Nonepisodic memory deficits in amnestic MCI. Cogn Behav Neurol 2007;20:99-106.
9.
Lonie JA, Herrmann LL, Tierney KM, Donaghey C, O'Carroll R, Lee A, Ebmeier KP: Lexical and semantic fluency discrepancy scores in aMCI and early Alzheimer's disease. J Neuropsychol 2009;3:79-92.
10.
Murphy KJ, Rich JB, Troyer AK: Verbal fluency patterns in amnestic mild cognitive impairment are characteristic of Alzheimer's type dementia. J Int Neuropsychol Soc 2006;12:570-574.
11.
Adlam AL, Bozeat S, Arnold R, Watson P, Hodges JR: Semantic knowledge in mild cognitive impairment and mild Alzheimer's disease. Cortex 2006;42:675-684.
12.
Nutter-Upham KE, Saykin AJ, Rabin LA, Roth RM, Wishart HA, Pare N, Flashman LA: Verbal fluency performance in amnestic MCI and older adults with cognitive complaints. Arch Clin Neuropsychol 2008;23:229-241.
13.
Brandt J, Manning KJ: Patterns of word-list generation in mild cognitive impairment and Alzheimer's disease. Clin Neuropsychol 2009;23:870-879.
14.
Clark LJ, Gatz M, Zheng L, Chen YL, McCleary C, Mack WJ: Longitudinal verbal fluency in normal aging, preclinical, and prevalent Alzheimer's disease. Am J Alzheimers Dis Other Demen 2009;24:461-468.
15.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
16.
Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, Leirer VO: Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1982;17:37-49.
17.
Beck AT, Steer RA, Brown GK: Beck Depression Inventory. San Antonio, The Psychological Corporation, 1996.
18.
Strauss E, Sherman EMS, Spreen O: A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary, ed 3. New York, Oxford University Press, 2006.
19.
Heaton RK, Miller SW, Taylor MJ, Grant I: Revised Comprehensive Norms for an expanded Halstead-Reitan Battery: Demographically Adjusted Neuropsychological Norms for African American and Caucasian Adults. Odessa, Psychological Assessment Resources, 2004.
20.
Loonstra AS, Tarlow AR, Sellers AH: Cowat metanorms across age, education, and gender. Appl Neuropsychol 2001;8:161-166.
21.
Tombaugh TN, Kozak J, Rees L: Normative data stratified by age and education for two measures of verbal fluency: Fas and animal naming. Arch Clin Neuropsychol 1999;14:167-177.
22.
Lezak MD, Howieson DB, Loring DW: Neuropsychological Assessment, ed 4. Oxford, Oxford University Press, 2004.
23.
Jak AJ, Bangen KJ, Wierenga CE, Delano-Wood L, Corey-Bloom J, Bondi MW: Contributions of neuropsychology and neuroimaging to understanding clinical subtypes of mild cognitive impairment. Int Rev Neurobiol 2009;84:81-103.
24.
Schinka JA, Loewenstein DA, Raj A, Schoenberg MR, Banko JL, Potter H, Duara R: Defining mild cognitive impairment: impact of varying decision criteria on neuropsychological diagnostic frequencies and correlates. Am J Geriatr Psychiatry 2010;18:684-691.
25.
Romero HR, Lageman SK, Kamath VV, Irani F, Sim A, Suarez P, Manly JJ, Attix DK: Challenges in the neuropsychological assessment of ethnic minorities: summit proceedings. Clin Neuropsychol 2009;23:761-779.
26.
Luo L, Luk G, Bialystok E: Effect of language proficiency and executive control on verbal fluency performance in bilinguals. Cognition 2010;114:29-41.
27.
Saxton J, Lopez OL, Ratcliff G, Dulberg C, Fried LP, Carlson MC, Newman AB, Kuller L: Preclinical Alzheimer disease: neuropsychological test performance 1.5 to 8 years prior to onset. Neurology 2004;63:2341-2347.
28.
Tierney MC, Yao C, Kiss A, McDowell I: Neuropsychological tests accurately predict incident Alzheimer disease after 5 and 10 years. Neurology 2005;64:1853-1859.
29.
Amieva H, Jacqmin-Gadda H, Orgogozo JM, Le Carret N, Helmer C, Letenneur L, Barberger-Gateau P, Fabrigoule C, Dartigues JF: The 9 year cognitive decline before dementia of the Alzheimer type: a prospective population-based study. Brain 2005;128:1093-1101.
30.
Auriacombe S, Lechevallier N, Amieva H, Harston S, Raoux N, Dartigues JF: A longitudinal study of quantitative and qualitative features of category verbal fluency in incident Alzheimer's disease subjects: results from the PAQUID study. Dement Geriatr Cogn Disord 2006;21:260-266.
31.
Loewenstein DA, Acevedo A, Agron J, Duara R: Vulnerability to proactive semantic interference and progression to dementia among older adults with mild cognitive impairment. Dement Geriatr Cogn Disord 2007;24:363-368.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.